Skip to main content
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Claim review

    Peptide longevity stack claims — review

    The longevity-stack space typically combines pineal peptides (Epitalon), mitochondrial-derived peptides (MOTS-c, Humanin, SS-31), copper peptides (GHK-Cu), and NAD+ precursors (NMN / NR). This page covers what they have in common: heavy marketing, mechanistic plausibility, and a near-complete absence of human longevity-outcome trial evidence.

    Common longevity-stack claims

    • “Reverses biological ageing”
    • “Lengthens telomeres”
    • “Restores mitochondrial function”
    • “Adds 10-20 years of healthspan”

    The honest picture

    Mechanistic-cell-and-rodent data exist for most longevity-stack peptides. Human Phase 3 outcome trials for any longevity endpoint do not. Russian observational data for Epitalon has not been independently replicated in Western trials.

    The evidence-based UK longevity intervention

    • Regular exercise (aerobic + resistance) — the strongest single intervention.
    • Mediterranean-style diet pattern.
    • Smoking cessation and alcohol moderation.
    • Sleep adequacy and quality.
    • Routine NHS Health Check (free, every 5 years for ages 40-74).
    • Cancer screening uptake — the highest-impact longevity intervention available in the UK.

    Frequently asked questions

    Do peptide longevity stacks extend human lifespan?
    No randomised human trial demonstrates that any peptide combination extends human lifespan. Mechanistic stories abound; outcome evidence is absent.
    What is the strongest-evidence longevity intervention?
    Regular aerobic + resistance exercise, Mediterranean-style diet, adequate sleep, smoking cessation, alcohol moderation, and routine cancer screening. None of these are peptides.
    Are these stacks legal in the UK?
    Most longevity-stack peptides (Epitalon, MOTS-c, Humanin, injectable GHK-Cu) are unlicensed in the UK. Sale with longevity claims engages UK medicines regulation.
    What about NMN / NR supplements?
    Oral NMN and NR raise NAD+ precursor levels modestly in human studies; clinical-outcome benefit (longevity, healthspan, disease prevention) is not yet demonstrated.
    What is the cancer-promotion concern?
    Sustained telomerase activation (Epitalon claim) and growth-factor pathway activation have theoretical oncologic concerns. Long-term human surveillance does not exist for any peptide longevity stack.

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    Related